Skip to main content
Premium Trial:

Request an Annual Quote

Sony Pulls [email protected] from PS3

A new software update for Sony's PlayStation 3 will signal the end of the system's support for [email protected], the distributed protein-folding project led by Vijay Pande's group at Stanford.

According to a Sony blog post, the 4.30 update for PS3, scheduled for rollout in November, will not offer the Life with PlayStation application that included the [email protected] client.

Sony says that more than 15 million users have participated in the PS3 [email protected] program since it started in 2007 and that PS3 users have donated than 100 million computation hours to the effort.

"Considering the contribution PS3 has made to the project, we decided the termination as a result of discussions with Stanford University," Sony says.

In a statement provided to Sony, Pande calls the PS3 partnership "a game changer for [email protected], as it opened the door for new methods and new processors, eventually also leading to the use of GPUs."

He cites a recent paper published in the Journal of Medicinal Chemistry describing how [email protected] simulations led to the development of a peptide with the potential to fight Alzheimer's disease and says that "the next steps, now underway at Stanford, are to take this lead compound and help push it towards a viable drug."

The [email protected] client is still available for use with PCs through the Stanford website.

HT: Cnet

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.